News & Updates

Show Multimedia Only
Canagliflozin holds promise against MAFLD in T2D patients

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023 byStephen Padilla

Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023
High red meat consumption increases risks of CVD and diabetes

High red meat consumption increases risks of CVD and diabetes

27 Oct 2023
Histologic margin status predicts relapse in lentigo maligna melanoma

Histologic margin status predicts relapse in lentigo maligna melanoma

26 Oct 2023